Susceptible vancomycin-resistant E. faecium (VREF) infections, nosocomial and community-acquired pneumonia, complicated skin and skin structure infections (including diabetic foot infections) without osteomyelitis, uncomplicated skin and skin structure infections.
Infuse inj over 30–120 minutes; switch to oral form when appropriate. VREF: 600mg every 12 hrs for 14–28 days. Pneumonia, complicated skin and skin structure: 600mg every 12 hrs for 10–14 days. Uncomplicated skin and skin structure (oral forms only): 12–17yrs: 600mg every 12 hrs; >17yrs: 400mg every 12 hrs; both for 10–14 days. MRSA: 600mg every 12 hrs.
Infuse inj over 30–120 minutes; switch to oral form when appropriate. Neonates <7 days: see literature. 0–11yrs: VREF: 10mg/kg every 8 hrs for 14–28 days; pneumonia, complicated skin and skin structure: 10mg/kg every 8 hrs for 10–14 days. Uncomplicated skin and skin structure (oral forms only): <5yrs: 10mg/kg every 8 hrs; 5–11yrs: 10mg/kg every 12 hrs; both for 10–14 days.
During or within 2 weeks of MAOIs (eg, phenelzine, isocarboxazid).
Not for treating catheter-related bloodstream infections or catheter-site infections. Uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome: not recommended. History of seizures. Monitor CBC's weekly (esp. if otherwise at risk). Consider discontinuing if myelosuppression occurs or worsens. Therapy >28 days. Peripheral and optic neuropathy. Monitor visual function if treatment ≥3 months and if new visual symptoms occur. Diabetes; monitor for hypoglycemia, if occurs, reduce dose or discontinue. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Concomitant sympathomimetics (eg, pseudoephedrine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergics (eg, dopamine, dobutamine): not recommended. Risk of serotonin syndrome with concomitant SSRIs, trycyclic antidepressants, triptans, meperidine, bupropion, or buspirone. Avoid large amounts of dietary tyramine (keep <100mg/meal). May be antagonized by carbamazepine, phenytoin, phenobarbital. Caution with myelosuppressants.
Diarrhea, nausea, headache, insomnia, constipation, rash, dizziness, pruritus, tongue discoloration, taste alteration; myelosuppression (eg, anemia, thrombocytopenia), lactic acidosis, C.difficile-associated diarrhea, hypoglycemia, blurred vision, convulsion.
Tabs—20, 100; Susp—150mL; Inj (100mL, 200mL, 300mL)—1